RBCC: Mobile Technology May Help Reduce Athletes’ Risk of Brain Injury
As Rainbow Coral Corp. (OTCBB: RBCC) works to help eliminate the public
health threat posed by traumatic brain injury (TBI), a new smartphone
app could prove key to reducing the serious risk of concussion faced by
athletes in contact sports.
Thanks in part to a $1.5 million government grant, Hockey Canada has
developed a new smartphone app aimed at keeping players safe from brain
injury. The app includes medically approved information on everything
from concussion symptoms to return-to-play protocols, designed to help
coaches, trainers and players quickly diagnose concussions suffered in
the course of play and respond accordingly.
Available across all mobile platforms, the app can be updated
immediately with the latest advances in TBI research, helping to keep
athletes as informed on concussions as leading doctors are.
“The potential for this technology to change the way concussions are
handled in sports is huge,” said RBCC CEO Patrick Brown. “Apps can be
customized not only for hockey, but for football and other rough sports
and deployed on sidelines and trainers’ rooms around the world
instantaneously. It’s precisely the kind of technological advance that
could help eliminate the risk of TBI to our athletes.”
RBCC is striving to capitalize on the growing demand for effective new
treatments for TBI and other neurological health issues. The company is
continuing discussions with the license holders for a NASA-developed
bioreactor that assists in the expansion of adult stem cells useful in
the development of potential cures. Such treatments could give RBCC
access to markets in excess of $100 billion.
Rainbow BioSciences is dedicated to developing new medical and research
technology innovations to compete alongside companies such as Amgen Inc.
(NASDAQ: AMGN), Cell Therapeutics, Inc. (NASDAQ: CTIC), Abbott
Laboratories (NYSE: ABT) and Affymax, Inc. (NASDAQ: AFFY).
Rainbow BioSciences is a division of Rainbow Coral Corp. (OTCBB: RBCC).
The company continually seeks out new partnerships with biotechnology
developers to deliver profitable new medical technologies and
innovations. For more information on our growth-oriented business
initiatives, please visit our website at www.rainbowbiosciences.com.
For investment information and performance data on the company, please
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act
of 1995: This news release contains forward-looking information within
the meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended,
including statements that include the words "believes," "expects,"
"anticipate" or similar expressions. Such forward-looking statements
involve known and unknown risks, uncertainties and other factors that
may cause the actual results, performance or achievements of the company
to differ materially from those expressed or implied by such
forward-looking statements. In addition, description of anyone's past
success, either financial or strategic, is no guarantee of future
success. This news release speaks as of the date first set forth above
and the company assumes no responsibility to update the information
included herein for events occurring after the date hereof.